SAN DIEGO, July 6, 2015 /PRNewswire/ -- OncoSec Medical
Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based
intratumoral cancer immunotherapies, today announced the
appointment of Joann V. Lofgren to
the newly created position of Vice President of Market Development,
effective July 6, 2015. In this role,
Ms. Lofgren will be responsible for evaluating, designing, and
executing on the company's market and product development strategy
for all therapeutic products.
"I'm very excited to welcome Joann to the OncoSec team and have
her lead the marketing and product development efforts for the
company," said Punit Dhillon,
President and CEO of OncoSec. "With extensive medical device
marketing experience, Joann has a proven track record for building
and commercializing products and therapies in the healthcare
industry that help provide long-term benefits for patients. Joann's
market and industry insights will be valuable additions as we
continue to advance our immuno-oncology clinical pipeline."
Most recently, Ms. Lofgren served as the Marketing Director for
Hansen Medical, where she developed and implemented strategic plans
to grow the sales of robotic systems and catheters in the
$1.5 billion global electrophysiology
ablation market. Prior to joining Hansen Medical, Ms. Lofgren
served as Group Marketing Manager at Abbott Vascular, a division of
Abbott, a diversified global healthcare company. While at Abbott
Vascular, she managed a commercial team responsible for its
$1.5 billion global interventional
cardiology product portfolio and created a long-term product
portfolio plan to maximize commercial opportunity while gaining
operational efficiency.
Ms. Lofgren earned a bachelor's degree in bioengineering from
the University of California, San Diego
and a master's degree in entrepreneurship and marketing from the
University of California, Los Angeles'
Anderson School of Management.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its investigational
ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core
technology is designed to enhance the local delivery and uptake of
DNA IL-12 and other DNA-based immune-targeting agents. Clinical
studies of ImmunoPulse™ IL-12 have demonstrated an acceptable
safety profile and evidence of anti-tumor activity in the treatment
of various skin cancers as well as the potential to initiate a
systemic immune response. OncoSec's lead program, ImmunoPulse™
IL-12, is currently in Phase II development for several
indications, including metastatic melanoma and squamous cell
carcinoma of the head and neck. In addition to ImmunoPulse™ IL-12,
the company is also identifying and developing new immune-targeting
agents for use with the ImmunoPulse™ platform. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-medical-appoints-joann-v-lofgren-as-vice-president-of-market-development-300108750.html
SOURCE OncoSec Medical Inc.